关键词: Aicardi-Goutières syndrome CANDLE syndrome Chilblains Engelures Familial chilblain lupus Interferon Interferonopathy Interféron Interféronopathie JASL syndrome JMP syndrome Lupus érythémateux systémique Lupus-engelure familial Nakajo-Nishimura syndrome PRAAS Proteasome-associated auto-inflammatory syndromes SAVI STING Singleton-Merten syndrome Spondyloenchondrodysplasia Spondyloenchondrodysplasie Syndrome CANDLE Syndrome JASL Syndrome JMP Syndrome Nakajo-Nishimura Syndrome SAVI Syndrome de Singleton-Merten Syndrome d’Aicardi-Goutières Syndromes auto-inflammatoires liés au protéasome Systemic lupus erythematosus Vascularite Vasculitis Vasculopathie Vasculopathy

Mesh : Aortic Diseases / immunology Autoimmune Diseases / immunology Autoimmune Diseases of the Nervous System / genetics immunology Chilblains / immunology Dental Enamel Hypoplasia / immunology Humans Interferon Type I / immunology Janus Kinases / antagonists & inhibitors Lupus Erythematosus, Cutaneous / immunology Metacarpus / abnormalities immunology Muscular Diseases / immunology Nervous System Malformations / genetics immunology Odontodysplasia / immunology Osteochondrodysplasias / immunology Osteoporosis / immunology Proteasome Endopeptidase Complex / immunology Reverse Transcriptase Inhibitors / therapeutic use Skin / pathology Syndrome Treatment Outcome Vascular Calcification / immunology

来  源:   DOI:10.1016/j.annder.2015.06.018

Abstract:
Type I interferonopathies are a group of Mendelian disorders characterized by a common physiopathology: the up-regulation of type I interferons. To date, interferonopathies include Aicardi-Goutières syndrome, familial chilblain lupus, spondyenchondromatosis, PRoteasome-associated auto-inflammatory syndrome (PRAAS) and Singleton-Merten syndrome. These diseases present phenotypic overlap including cutaneous features like chilblain lupus, that can be inaugural or present within the first months of life. This novel set of inborn errors of immunity is evolving rapidly, with recognition of new diseases and genes. Recent and improved understanding of the physiopathology of overexpression of type I interferons has allowed the development of targeted therapies, currently being evaluated, like Janus-kinases or reverse transcriptase inhibitors.
摘要:
暂无翻译
公众号